IBIO Stock Forecast: iBio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for iBio, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 32 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores iBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (67): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (9): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IBIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Sept 2026 | HC Wainwright & Co. | Initiates | Buy | $7.00 |
| 2 July 2026 | Chardan Capital | Maintains | Buy | $5.00 |
| 8 June 2026 | Raymond James | Initiates | Outperform | — |
| 9 Apr 2026 | Chardan Capital | Maintains | Buy | — |
| 18 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 3 Mar 2026 | Jones Trading | Initiates | Buy | — |
| 12 Feb 2026 | Chardan Capital | Maintains | Buy | — |
| 21 Oct 2025 | Oppenheimer | Initiates | Outperform | — |
| 17 Oct 2025 | Leerink Partners | Initiates | Outperform | — |
| 25 June 2025 | Chardan Capital | Maintains | Buy | — |
| 6 May 2025 | Chardan Capital | Maintains | Buy | — |
| 5 May 2025 | Chardan Capital | Maintains | Buy | — |
| 17 Dec 2024 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 22 July 2024 | Brookline Capital | Initiates | Buy | — |
| 3 June 2024 | Chardan Capital | Maintains | Buy | — |
| 28 May 2024 | Chardan Capital | Initiates | Buy | — |
| 16 Feb 2023 | JMP Securities | Downgrade | Market Perform | — |
| 7 Oct 2022 | Cantor Fitzgerald | Downgrade | Neutral | $2.50 → $0.17 |
| 29 Nov 2021 | JMP Securities | Initiates | Outperform | $1.50 |
| 22 Jan 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IBIO.
This page is one stock. Monday covers all of them.
IBIO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IBIO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, iBio, Inc. returned −20.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IBIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 52.4×
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 5% of US stocks
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −51.8%
- Return on assets
- −26.6%
- Dividend yield
- —
Higher than 21% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
iBio, Inc. has a market value of $56.4M.
Revenue in the twelve months to 30 June 2026: $100K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$33.0M, a −33044.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$23.8M.
iBio, Inc. employs 23 people — $4K of revenue per employee.
Data provided by Twelve Data
IBIO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IBIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own iBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IBIO
What is the IBIO stock price forecast for 2026-2027?
The median 12-month analyst price target for iBio, Inc. is $6, with estimates ranging from $4.2 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IBIO stock a buy right now?
Of the 9 analysts covering iBio, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks iBio, Inc. 32 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IBIO?
As at 21 Nov 2026, iBio, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (67 of 100).
Will IBIO stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts is $6, and Ticker Nerd's factor model ranks iBio, Inc. 32 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IBIO stock forecast for 2030?
No analyst covering iBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.2 to $7 over the next 12 months.
How has IBIO stock performed over the past year?
iBio, Inc. returned -20.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does iBio, Inc. do?
iBio, Inc. is a biotechnology company focused on developing precision antibodies and other next-generation biologics for obesity, cardiometabolic disease, cancer, and other hard-to-treat conditions. The company uses artificial intelligence, advanced computational biology, and proprietary discovery platforms to identify and optimize antibody candidates against challenging therapeutic targets.
About iBio, Inc.
iBio, Inc. is a biotechnology company focused on developing precision antibodies and other next-generation biologics for obesity, cardiometabolic disease, cancer, and other hard-to-treat conditions. The company uses artificial intelligence, advanced computational biology, and proprietary discovery platforms to identify and optimize antibody candidates against challenging therapeutic targets. Its current technology stack includes platforms designed for antibody engineering, masking, optimization, and epitope steering, which support preclinical research and early-stage pipeline development. iBio’s work is centered on improving the speed and precision of drug discovery for complex diseases, with an emphasis on antibody-based therapies and related biopharmaceutical programs. Founded in 2008 and headquartered in San Diego, California, iBio plays a niche role in the biotechnology market as a research-driven company advancing AI-enabled biologic discovery.
CEO Dr. Martin B. Brenner D.V.M., Ph.D. · 23 employees · United States · https://ibioinc.com